The search for circulating biomarkers that improve the care of patients with chronic kidney disease (CKD) remains active. The ideal biomarker would be widely available, be easy to measure, provide novel insights into the patient’s condition, and help tailor therapies.1 Could brain natriuretic peptide (BNP) function as this ideal CKD biomarker?